Terbinafine Therapeutic Cheat Sheet
terbinafine
by Adrianna Gonzalez Lopez, MD on
Dermatophyte infections are estimated to affect about 25% of the world’s population, representing some of the most common infections in the world. Conditions such as onychomycosis and tinea capitis may significantly impact quality of life by way of their symptoms or appearance, making adequate treatment important. Oral and topical formulations of terbinafine are commonly used on- and off-label f …
Dupilumab Therapeutic Cheat Sheet
Dupilumab
by Azam Qureshi, MD on
Atopic dermatitis (AD) is a common skin condition characterized by pruritus and occurs as a result of factors related to impaired skin barrier and immune response, as well as environmental and infectious agents. Patients with poor control on topical therapy are looking for safe and effective systemic treatments. We continue our series, Therapeutic Cheat Sheet, with a closer look at dupilumab, whic …
5-Fluorouracil Therapeutic Cheat Sheet
Fluoroplex
by Blair Allais, MD on
Actinic keratoses represent the most common dermatologic diagnosis in patients older than 45 years old in the United States and account for 5.2 million visits annually.1 Cutaneous field cancerization represents areas with a high burden of both clinical and subclinical actinic damage. Cryotherapy can often be combined with topical chemotherapy for a synergistic approach. We continue our series, The …
Glycopyrronium Tosylate Cloth for Hyperhidrosis Therapeutic Cheat Sheet
Qbrexza Therapeutic Cheat Sheet
by Blair Allais, MD on
Hyperhidrosis affects approximately 4.8% of the U.S. population1 and causes patients significant psychosocial distress. Patients are looking to maximize non-invasive treatment options while avoiding systemic side effects. We continue our series, Therapeutic Cheat Sheet, with a closer look at glycopyrronium tosylate cloths. [caption id="attachment_11862" align="alignleft" width="1934"] Click ima …
Mycophenolate Mofetil Therapeutic Cheat Sheet
Mycophenolate Mofetil
by Blair Allais, MD on
When standard treatment options fail and corticosteroids are not a long-term option, dermatologists often have to look back to their tool-kit and pull out the “big guns.” Mycophenolate mofetil has emerged as a promising immunosuppressive agent for severe immune-mediated and inflammatory dermatologic disease. We continue our series, Therapeutic Cheat Sheet, with a closer look at mycophenolate m …